Cargando…
Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
Despite being the least abundant immunoglobulin G in human plasma, IgG4 are used therapeutically when weak effector functions are needed. The increase in engineered IgG4-based antibodies on the market led us to study the patent landscape of IgG4 Fc engineering, i.e., patents claiming modifications i...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816381/ https://www.ncbi.nlm.nih.gov/pubmed/31556789 http://dx.doi.org/10.1080/19420862.2019.1664365 |